Cost-Effectiveness Analysis of Peginterferon Beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis in Italy: Results of an Updated Analysis

Farmeconomia. Health economics and therapeutic pathways
doi 10.7175/fe.v19i1.1385
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Seed SRL

Related search

Pnd33 - Payer and Societal Benefit of Peginterferon Beta-1a Versus Glatiramer Acetate in Patients With Relapsing-Remitting Multiple Sclerosis in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost-Effectiveness of Glatiramer Acetate and Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis, Based on the Combirx Study

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Budget Impact Analysis of Delayed-Release Dimethylfumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Pnd60 - Cost-Effectiveness of Teriflunomide for the Treatment of Relapsing-Remitting Multiple Sclerosis in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pnd34 - Payer and Societal Benefit of Peginterferon Beta-1a Versus Glatiramer Acetate in Patients With Relapsing-Remitting Multiple Sclerosis in Spain

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pnd72 - Cost-Minimization Analysis of Teriflunomide and Dimethyl Fumarate for Treatment of Relapsing-Remitting Forms of Multiple Sclerosis in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Real-Life Effectiveness of Natalizumab in Relapsing-Remitting Multiple Sclerosis (Rrms): A Registry Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Pnd73 - The Impact of Modelling Subsequent Treatment on Estimates of Cost-Effectiveness: An Analysis of Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis in the United Kingdom

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Comparing the Cost-Effectiveness of Disease-Modifying Drugs for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis

Journal of Managed Care Pharmacy
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy